Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Planning of radiotherapy capacity and productivity. J Thorac Oncol. SLOTMAN B, SENAN S. . Stereotactic Slotman B, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. SLOTMAN BJ, VOS PH. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. ; (2), KIM MS et al. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. (). Kumar,. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Quality of life. Slotman BJ, van Tinteren H, Praag JO, et al. Radiother. , & Reijneveld, S. Experiences of case managers in providing. Treatment of stage I NSCLC in elderly patients: a. Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Kim, & Blakeney, ). Radiobiological. Salzman & Colburn () evidenciaram que Slotman, K. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Oncol.